Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intracranial Aneurysm | 5 | 2022 | 47 | 2.790 |
Why?
|
| Subarachnoid Hemorrhage | 5 | 2023 | 65 | 1.880 |
Why?
|
| Aneurysm, Ruptured | 2 | 2023 | 18 | 1.690 |
Why?
|
| Vasospasm, Intracranial | 2 | 2023 | 15 | 1.050 |
Why?
|
| Embolization, Therapeutic | 2 | 2022 | 86 | 0.890 |
Why?
|
| Radiation Injuries | 2 | 2022 | 112 | 0.880 |
Why?
|
| Endoscopy | 6 | 2020 | 124 | 0.830 |
Why?
|
| Pancreatic Elastase | 1 | 2021 | 15 | 0.750 |
Why?
|
| Carotid Artery Diseases | 1 | 2021 | 33 | 0.740 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2021 | 76 | 0.730 |
Why?
|
| Rabbits | 1 | 2021 | 374 | 0.700 |
Why?
|
| Skull Base | 6 | 2021 | 31 | 0.670 |
Why?
|
| Brain Neoplasms | 2 | 2018 | 288 | 0.610 |
Why?
|
| Neurosurgical Procedures | 3 | 2020 | 121 | 0.600 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 154 | 0.560 |
Why?
|
| Neuroendoscopy | 1 | 2016 | 7 | 0.530 |
Why?
|
| Cerebral Arteries | 1 | 2016 | 40 | 0.520 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 1458 | 0.510 |
Why?
|
| Retrospective Studies | 16 | 2024 | 6134 | 0.460 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 605 | 0.420 |
Why?
|
| Intracranial Hypertension | 2 | 2022 | 31 | 0.390 |
Why?
|
| Hydrocephalus | 2 | 2008 | 42 | 0.380 |
Why?
|
| Dwarfism | 1 | 2010 | 4 | 0.360 |
Why?
|
| Spinal Cord Compression | 1 | 2010 | 10 | 0.360 |
Why?
|
| Bone Diseases, Developmental | 1 | 2010 | 14 | 0.360 |
Why?
|
| Thoracic Vertebrae | 1 | 2010 | 36 | 0.350 |
Why?
|
| Sacrum | 1 | 2010 | 19 | 0.350 |
Why?
|
| Surgical Instruments | 2 | 2022 | 28 | 0.340 |
Why?
|
| Spinal Cord | 1 | 2010 | 177 | 0.330 |
Why?
|
| Central Nervous System Vascular Malformations | 2 | 2022 | 13 | 0.330 |
Why?
|
| Lumbar Vertebrae | 1 | 2010 | 98 | 0.330 |
Why?
|
| Skull Base Neoplasms | 3 | 2020 | 21 | 0.330 |
Why?
|
| Dandy-Walker Syndrome | 1 | 2008 | 3 | 0.320 |
Why?
|
| Osteogenesis Imperfecta | 1 | 2008 | 38 | 0.300 |
Why?
|
| Developmental Disabilities | 1 | 2008 | 119 | 0.290 |
Why?
|
| Brain | 3 | 2017 | 1328 | 0.290 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2016 | 1541 | 0.270 |
Why?
|
| Humans | 24 | 2024 | 50208 | 0.260 |
Why?
|
| Postoperative Complications | 4 | 2020 | 996 | 0.250 |
Why?
|
| Male | 16 | 2021 | 25399 | 0.240 |
Why?
|
| N-Methylaspartate | 1 | 2003 | 27 | 0.220 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2003 | 20 | 0.220 |
Why?
|
| Cerebral Infarction | 1 | 2023 | 39 | 0.220 |
Why?
|
| Necrosis | 2 | 2021 | 178 | 0.220 |
Why?
|
| Adult | 9 | 2022 | 13324 | 0.190 |
Why?
|
| Female | 14 | 2022 | 26635 | 0.190 |
Why?
|
| Tunica Media | 1 | 2021 | 10 | 0.190 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2021 | 15 | 0.190 |
Why?
|
| Elastic Tissue | 1 | 2021 | 10 | 0.190 |
Why?
|
| Seizures | 1 | 2003 | 196 | 0.190 |
Why?
|
| Vasculitis | 1 | 2021 | 29 | 0.190 |
Why?
|
| Verapamil | 1 | 2020 | 22 | 0.190 |
Why?
|
| Carotid Artery, Common | 1 | 2021 | 44 | 0.180 |
Why?
|
| Single-Blind Method | 1 | 2021 | 115 | 0.180 |
Why?
|
| Hyperplasia | 1 | 2021 | 96 | 0.180 |
Why?
|
| Tunica Intima | 1 | 2021 | 55 | 0.180 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2021 | 86 | 0.180 |
Why?
|
| Obesity, Morbid | 1 | 2021 | 78 | 0.180 |
Why?
|
| Regeneration | 1 | 2021 | 72 | 0.180 |
Why?
|
| Encephalocele | 2 | 2020 | 12 | 0.170 |
Why?
|
| Aspirin | 1 | 2021 | 114 | 0.170 |
Why?
|
| Intraoperative Complications | 1 | 2020 | 112 | 0.170 |
Why?
|
| Sex Characteristics | 1 | 2021 | 191 | 0.170 |
Why?
|
| Nasal Surgical Procedures | 1 | 2018 | 2 | 0.160 |
Why?
|
| Orbit | 1 | 2018 | 29 | 0.160 |
Why?
|
| Nose | 2 | 2016 | 31 | 0.160 |
Why?
|
| Treatment Outcome | 9 | 2021 | 5155 | 0.160 |
Why?
|
| Adrenal Insufficiency | 2 | 2008 | 18 | 0.150 |
Why?
|
| Aged | 7 | 2023 | 9405 | 0.150 |
Why?
|
| Disease Progression | 1 | 2021 | 831 | 0.150 |
Why?
|
| Cerebrospinal Fluid Rhinorrhea | 2 | 2016 | 6 | 0.150 |
Why?
|
| Surgical Flaps | 2 | 2016 | 120 | 0.130 |
Why?
|
| Child | 5 | 2020 | 6851 | 0.130 |
Why?
|
| Nose Neoplasms | 1 | 2016 | 5 | 0.130 |
Why?
|
| Pituitary Gland | 1 | 2016 | 86 | 0.130 |
Why?
|
| Immunotherapy | 1 | 2017 | 240 | 0.130 |
Why?
|
| Meningocele | 1 | 2015 | 7 | 0.130 |
Why?
|
| Brain Stem | 1 | 2015 | 57 | 0.120 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 2190 | 0.120 |
Why?
|
| Pterygopalatine Fossa | 1 | 2014 | 1 | 0.120 |
Why?
|
| Edema | 1 | 2015 | 69 | 0.120 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2014 | 4 | 0.120 |
Why?
|
| Feasibility Studies | 1 | 2016 | 380 | 0.120 |
Why?
|
| Nasal Septum | 1 | 2014 | 8 | 0.120 |
Why?
|
| Nasal Mucosa | 1 | 2014 | 19 | 0.110 |
Why?
|
| Melanoma | 1 | 2017 | 290 | 0.110 |
Why?
|
| Comorbidity | 3 | 2015 | 613 | 0.110 |
Why?
|
| Child, Preschool | 3 | 2020 | 3883 | 0.110 |
Why?
|
| Incidence | 3 | 2018 | 1006 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 460 | 0.110 |
Why?
|
| Angiography, Digital Subtraction | 2 | 2024 | 27 | 0.100 |
Why?
|
| Infant, Newborn | 3 | 2022 | 2766 | 0.100 |
Why?
|
| Cervical Vertebrae | 2 | 2008 | 58 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2014 | 613 | 0.090 |
Why?
|
| Adolescent | 4 | 2020 | 6390 | 0.090 |
Why?
|
| Kyphosis | 1 | 2010 | 15 | 0.090 |
Why?
|
| Neurologic Examination | 1 | 2010 | 77 | 0.090 |
Why?
|
| Cerebral Angiography | 2 | 2024 | 97 | 0.090 |
Why?
|
| Reference Values | 1 | 2010 | 310 | 0.090 |
Why?
|
| Neurosurgery | 1 | 2009 | 32 | 0.080 |
Why?
|
| Spinal Fusion | 1 | 2010 | 70 | 0.080 |
Why?
|
| Animals | 2 | 2021 | 13246 | 0.080 |
Why?
|
| Cranial Fossa, Posterior | 1 | 2008 | 7 | 0.080 |
Why?
|
| Urogenital Abnormalities | 1 | 2008 | 17 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2014 | 1422 | 0.080 |
Why?
|
| Severity of Illness Index | 2 | 2008 | 951 | 0.080 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2008 | 26 | 0.080 |
Why?
|
| Occipital Bone | 1 | 2008 | 4 | 0.080 |
Why?
|
| Hematoma, Epidural, Cranial | 1 | 2008 | 7 | 0.080 |
Why?
|
| Hematoma, Subdural | 1 | 2008 | 21 | 0.080 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2008 | 21 | 0.080 |
Why?
|
| North Carolina | 2 | 2018 | 52 | 0.080 |
Why?
|
| Pharmacists | 1 | 2009 | 144 | 0.080 |
Why?
|
| Craniotomy | 1 | 2008 | 25 | 0.080 |
Why?
|
| Neck Injuries | 1 | 2008 | 21 | 0.080 |
Why?
|
| Skull | 1 | 2008 | 75 | 0.080 |
Why?
|
| Decompression, Surgical | 1 | 2008 | 51 | 0.080 |
Why?
|
| Spinal Fractures | 1 | 2008 | 38 | 0.070 |
Why?
|
| Spinal Cord Injuries | 1 | 2008 | 55 | 0.070 |
Why?
|
| Gastrointestinal Diseases | 1 | 2008 | 126 | 0.070 |
Why?
|
| Abnormalities, Multiple | 1 | 2008 | 167 | 0.070 |
Why?
|
| Middle Aged | 6 | 2020 | 12206 | 0.070 |
Why?
|
| Infant | 2 | 2020 | 3563 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 636 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 3154 | 0.060 |
Why?
|
| Length of Stay | 3 | 2015 | 621 | 0.060 |
Why?
|
| Recurrence | 2 | 2016 | 662 | 0.060 |
Why?
|
| Pentylenetetrazole | 1 | 2003 | 9 | 0.050 |
Why?
|
| Convulsants | 1 | 2003 | 7 | 0.050 |
Why?
|
| Maze Learning | 1 | 2003 | 32 | 0.050 |
Why?
|
| Radiation Dosage | 1 | 2024 | 157 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 443 | 0.050 |
Why?
|
| Status Epilepticus | 1 | 2003 | 39 | 0.050 |
Why?
|
| Coma | 1 | 2022 | 14 | 0.050 |
Why?
|
| Pentobarbital | 1 | 2022 | 28 | 0.050 |
Why?
|
| Animals, Newborn | 1 | 2003 | 368 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2003 | 215 | 0.050 |
Why?
|
| Electroencephalography | 1 | 2003 | 307 | 0.050 |
Why?
|
| Pituitary Diseases | 1 | 2020 | 2 | 0.050 |
Why?
|
| Perforator Flap | 1 | 2020 | 2 | 0.050 |
Why?
|
| Perfusion Imaging | 1 | 2020 | 8 | 0.050 |
Why?
|
| Risk Factors | 2 | 2020 | 3629 | 0.050 |
Why?
|
| Phenotype | 1 | 2003 | 733 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2016 | 1161 | 0.040 |
Why?
|
| Tracheostomy | 1 | 2020 | 71 | 0.040 |
Why?
|
| Neurons | 1 | 2003 | 460 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2003 | 1586 | 0.040 |
Why?
|
| Young Adult | 2 | 2020 | 3981 | 0.040 |
Why?
|
| Sex Factors | 1 | 2020 | 697 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2008 | 94 | 0.040 |
Why?
|
| Stereotaxic Techniques | 1 | 2017 | 37 | 0.040 |
Why?
|
| Age Factors | 1 | 2020 | 1092 | 0.040 |
Why?
|
| Equipment Failure Analysis | 1 | 2017 | 46 | 0.040 |
Why?
|
| Acute Disease | 2 | 2008 | 368 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2017 | 133 | 0.040 |
Why?
|
| Age Distribution | 1 | 2017 | 168 | 0.040 |
Why?
|
| Hospital Mortality | 2 | 2009 | 407 | 0.040 |
Why?
|
| Rats | 1 | 2003 | 3299 | 0.030 |
Why?
|
| Equipment Design | 1 | 2017 | 285 | 0.030 |
Why?
|
| Survival Rate | 1 | 2018 | 901 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2017 | 250 | 0.030 |
Why?
|
| Cranial Fossa, Anterior | 1 | 2014 | 5 | 0.030 |
Why?
|
| Nasal Cavity | 1 | 2014 | 9 | 0.030 |
Why?
|
| Infratentorial Neoplasms | 1 | 2014 | 5 | 0.030 |
Why?
|
| Angiofibroma | 1 | 2014 | 5 | 0.030 |
Why?
|
| Neurilemmoma | 1 | 2014 | 24 | 0.030 |
Why?
|
| Pregnancy | 1 | 2022 | 2604 | 0.030 |
Why?
|
| Temporal Lobe | 1 | 2014 | 70 | 0.030 |
Why?
|
| Prevalence | 1 | 2017 | 951 | 0.030 |
Why?
|
| Endovascular Procedures | 1 | 2015 | 174 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2014 | 1262 | 0.020 |
Why?
|
| Cosyntropin | 1 | 2008 | 2 | 0.020 |
Why?
|
| Intracranial Pressure | 1 | 2008 | 30 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2009 | 273 | 0.020 |
Why?
|
| Hydrocortisone | 1 | 2008 | 107 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2009 | 222 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2009 | 257 | 0.020 |
Why?
|